Augmentation Options for Fluoxetine 60mg
Lithium is the most established augmentation agent for fluoxetine 60mg when treating depression, with guideline support for enhancing antidepressant efficacy. 1
Primary Augmentation Strategy: Lithium
For treatment-resistant depression on fluoxetine 60mg, add lithium starting at 150mg daily, targeting blood levels of 0.2-0.6 mEq/L (typically achieved with 150-300mg/day). 1 This approach is specifically recommended in guidelines for augmenting antidepressant drugs when initial monotherapy proves insufficient.
Dosing Algorithm for Lithium Augmentation:
- Start: 150mg daily
- Monitor blood levels weekly initially
- Target: 0.2-0.6 mEq/L (lower than traditional bipolar dosing)
- Adjust dose based on levels and tolerability
- Critical caveat: Elderly patients are prone to neurotoxicity even at these lower doses—use extra caution and closer monitoring 1
Alternative Augmentation Options
For Depression with Specific Features:
Bupropion SR augmentation is supported by high-quality evidence from the STAR*D trial, showing similar efficacy to other augmentation strategies 2. This is particularly useful if:
- Patient has low energy/apathy
- Sexual dysfunction is problematic on fluoxetine
- Avoid if seizure history or significant agitation present
Buspirone augmentation also showed equivalent efficacy in STAR*D 2, though it had higher discontinuation rates (20.6%) compared to bupropion (12.5%) due to adverse effects.
For OCD (if that's the indication):
The evidence strongly supports antipsychotic augmentation for treatment-resistant OCD on fluoxetine 60mg. 3 Specifically:
- Aripiprazole: Most evidence-based choice, start 2.5-5mg daily, max 15mg
- Risperidone: Start 0.25mg at bedtime, max 2-3mg daily (watch for extrapyramidal symptoms above 2mg) 1
- Olanzapine: Start 2.5mg at bedtime, max 10mg daily 1
Memantine showed the strongest effect size in network meta-analysis for OCD augmentation (MD -8.94 points on Y-BOCS) 3, though it's less commonly used in practice.
For Anxiety Disorders:
Cognitive behavioral therapy (CBT) augmentation is the evidence-based choice, showing equivalent or superior outcomes to medication-only approaches 4. The CAMS trial demonstrated that combination CBT plus SSRI improved response and remission rates compared to either treatment alone.
Short-term benzodiazepine augmentation (clonazepam 0.5-1mg) during the first 3 weeks can accelerate response and improve tolerability 5, then taper off by week 4-5. This strategy:
- Reduces early SSRI side effects
- May improve compliance
- Shows modest, transitory taper effects when discontinued properly
Critical Safety Considerations
Avoid These Combinations:
- Never combine with MAOIs (phenelzine, isocarboxazid, linezolid)—absolute contraindication due to serotonin syndrome risk 4
- Exercise extreme caution with multiple serotonergic agents (tramadol, triptans, other antidepressants)
- Monitor closely for serotonin syndrome symptoms: confusion, agitation, tremors, hyperreflexia, autonomic instability 4
Drug Interactions:
Fluoxetine inhibits CYP2D6, so be cautious augmenting with agents metabolized by this pathway 4. Start augmentation agents at low doses and titrate slowly, monitoring especially in the first 24-48 hours after dose changes.
When Augmentation Fails
If adequate trials of augmentation strategies fail, switch to a different antidepressant rather than continuing to augment. 2 The STAR*D trial showed that switching to bupropion SR, sertraline, or venlafaxine XR produced similar efficacy to augmentation strategies, with potentially fewer medication interactions.
Consider referral to a psychiatrist or specialized mood disorders clinic if multiple augmentation attempts prove unsuccessful 6.